Business Description
Fulgent Genetics Inc
NAICS : 621511
SIC : 8071
ISIN : US3596641098
Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 161.87 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.34 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 125.7 | |||||
| 3-Year EBITDA Growth Rate | 325.2 | |||||
| 3-Year FCF Growth Rate | 219.7 | |||||
| 3-Year Book Growth Rate | 123.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.32 | |||||
| 9-Day RSI | 61.17 | |||||
| 14-Day RSI | 58.53 | |||||
| 6-1 Month Momentum % | -38.92 | |||||
| 12-1 Month Momentum % | -31.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.95 | |||||
| Quick Ratio | 8.87 | |||||
| Cash Ratio | 7.62 | |||||
| Days Inventory | 10.12 | |||||
| Days Sales Outstanding | 72.52 | |||||
| Days Payable | 36.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 | |||||
| Shareholder Yield % | 1.09 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 32.2 | |||||
| Operating Margin % | -28.28 | |||||
| Net Margin % | -22.17 | |||||
| FCF Margin % | 7.49 | |||||
| ROE % | -5.02 | |||||
| ROA % | -4.61 | |||||
| ROIC % | -10.2 | |||||
| ROC (Joel Greenblatt) % | -80.97 | |||||
| ROCE % | -6.25 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.94 | |||||
| PB Ratio | 0.66 | |||||
| Price-to-Tangible-Book | 0.86 | |||||
| Price-to-Free-Cash-Flow | 40.04 | |||||
| Price-to-Operating-Cash-Flow | 18.54 | |||||
| EV-to-EBIT | -4.36 | |||||
| EV-to-Forward-EBIT | -5.61 | |||||
| EV-to-EBITDA | -6.84 | |||||
| EV-to-Forward-EBITDA | -10.52 | |||||
| EV-to-Revenue | 1.23 | |||||
| EV-to-Forward-Revenue | 1.21 | |||||
| EV-to-FCF | 16.29 | |||||
| Price-to-Projected-FCF | 0.28 | |||||
| Price-to-Net-Current-Asset-Value | 1.86 | |||||
| Price-to-Net-Cash | 2.28 | |||||
| Earnings Yield (Greenblatt) % | -22.94 | |||||
| FCF Yield % | 2.58 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FLGT
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fulgent Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 286.412 | ||
| EPS (TTM) ($) | -2.14 | ||
| Beta | 1.17 | ||
| Volatility % | 51.85 | ||
| 14-Day RSI | 58.53 | ||
| 14-Day ATR ($) | 0.790004 | ||
| 20-Day SMA ($) | 26.7925 | ||
| 12-1 Month Momentum % | -31.69 | ||
| 52-Week Range ($) | 23.09 - 44.09 | ||
| Shares Outstanding (Mil) | 29.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fulgent Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fulgent Genetics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fulgent Genetics Inc Frequently Asked Questions
What is Fulgent Genetics Inc(FLGT)'s stock price today?
The current price of FLGT is $27.84. The 52 week high of FLGT is $44.09 and 52 week low is $23.09.
When is next earnings date of Fulgent Genetics Inc(FLGT)?
The next earnings date of Fulgent Genetics Inc(FLGT) is 2024-02-28 Est..
Does Fulgent Genetics Inc(FLGT) pay dividends? If so, how much?
Fulgent Genetics Inc(FLGT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers